Cardiovascular Segment by Application to Grow at Faster Pace During Forecast Period
According to a new market research study of “RNAi Therapeutics Market to 2027 - Global Analysis and Forecast by Molecule Type, Application, Route of Administration, and End User,” the market is expected to reach US$ 1,209.29 million by 2027 from US$ 618.79 million in 2019. The market is estimated to grow at a CAGR of 8.8% from 2020 to 2027. The report highlights trends prevailing in the global RNAi therapeutics market and the factors driving market along with those that act as hindrances.
Based on application, the global RNAi therapeutics market is segmented into oncology, cardiovascular, respiratory disorders, renal diseases, genetic disorders, neurodegenerative disorders, infectious diseases, and others.The oncology segment held the largest share of the market in 2019; whereas, the cardiovascular segmentis estimated to register the highest CAGR in the market during the forecast period. Factors such as increasing prevalence of cardiovascular diseases coupled with rising demand for superior alternative for the treatment of cardiovascular conditions is expected to boost the segment growth. Moreover, increasing research and development activities in order to validate the feasibility of RNAi therapies for cardiovascular conditions are projected to drive the cardiovascular application segment.
RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes thatare responsible for diseases. At present, the awareness about RNAi is increasing due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the market growth during the forecast period. However, high cost of RNAi therapy development is anticipated to hamper the market growth.
The global impacts of COVID-19 are being felt across several markets. In case of pharmaceutical industry, supply chain operations are significantly hampered due to the pandemic. However, market players in the RNAi therapeutics are focusing on the development of vaccine with the help of gene silencing technology, which might have a positive impact on the market growth during the forecast period.
Alnylam Pharmaceuticals, Inc.; Sanofi, Olix Pharmaceuticals, Inc.; Glaxosmithkline Plc.; Benitec Biopharma; Arbutus Biopharma Corporation; Silence Therapeutics; Rexahn Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc; and Quark are among the leading companies operating in the RNAi therapeutics market.
The Report Segments Global RNAi Therapeutics Market as follows:
By Molecule Type
By Application
By Route of Administration
By End User
By Geography
Reasons to Buy:
According to a new market research study of “RNAi Therapeutics Market to 2027 - Global Analysis and Forecast by Molecule Type, Application, Route of Administration, and End User,” the market is expected to reach US$ 1,209.29 million by 2027 from US$ 618.79 million in 2019. The market is estimated to grow at a CAGR of 8.8% from 2020 to 2027. The report highlights trends prevailing in the global RNAi therapeutics market and the factors driving market along with those that act as hindrances.
Based on application, the global RNAi therapeutics market is segmented into oncology, cardiovascular, respiratory disorders, renal diseases, genetic disorders, neurodegenerative disorders, infectious diseases, and others.The oncology segment held the largest share of the market in 2019; whereas, the cardiovascular segmentis estimated to register the highest CAGR in the market during the forecast period. Factors such as increasing prevalence of cardiovascular diseases coupled with rising demand for superior alternative for the treatment of cardiovascular conditions is expected to boost the segment growth. Moreover, increasing research and development activities in order to validate the feasibility of RNAi therapies for cardiovascular conditions are projected to drive the cardiovascular application segment.
RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes thatare responsible for diseases. At present, the awareness about RNAi is increasing due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the market growth during the forecast period. However, high cost of RNAi therapy development is anticipated to hamper the market growth.
The global impacts of COVID-19 are being felt across several markets. In case of pharmaceutical industry, supply chain operations are significantly hampered due to the pandemic. However, market players in the RNAi therapeutics are focusing on the development of vaccine with the help of gene silencing technology, which might have a positive impact on the market growth during the forecast period.
Alnylam Pharmaceuticals, Inc.; Sanofi, Olix Pharmaceuticals, Inc.; Glaxosmithkline Plc.; Benitec Biopharma; Arbutus Biopharma Corporation; Silence Therapeutics; Rexahn Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc; and Quark are among the leading companies operating in the RNAi therapeutics market.
The Report Segments Global RNAi Therapeutics Market as follows:
By Molecule Type
- Small Interfering RNAs (siRNA)
- MicroRNA (miRNA)
By Application
- Oncology
- Cardiovascular
- Respiratory Disorders
- Renal Diseases
- Genetic Disorders
- Neurodegenerative Disorders
- Infectious Diseases
- Others
By Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intradermal Injections
- Intraperitoneal Injections
- Others
By End User
- Research and Academic Laboratories
- Hospitals
- Diagnostic Laboratories
By Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- U.K
- Spain
- Italy
- Asia Pacific (APAC)
- China
- India
- Japan
- Australia
- South Korea
- Middle East & Africa (MEA)
- Saudi Arabia
- U.A.E
- South Africa
- South & Central America (SCAM)
- Brazil
- Argentina
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the RNAi therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global RNAI therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Global RNAi Therapeutics Market - Market Landscape
5. RNAi Therapeutics Market- Key Market Dynamics
6. RNAi Therapeutics Market - Global Analysis
7. RNAi Therapeutics Market- Molecule Type
8. RNAi Therapeutics Market- Application
9. RNAi Therapeutics Market Market- Route of Administration
10. RNAi Therapeutics Market Market- End User
11. RNAi Therapeutics Market - Geographic Analysis
12. Impact of COVID-19 Pandemic on Global RNAi Therapeutics Market
13. RNAi Therapeutics Market -Industry Landscape
14. Company Profiles
15. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Olix Pharmaceuticals, Inc.
- Glaxosmithkline Plc.
- Benitec Biopharma
- Arbutus Biopharma Corporation
- Silence Therapeutics
- Rexahn Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc
- Quark
